Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza

Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models

(2021) Kirill V. Kalnin et al.   npj Vaccines

Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination

(2021) Rishi R. Goel et al.   Science Immunology

The promise of mRNA vaccines: a biotech and industrial perspective

(2020) Nicholas A. C. Jackson et al.   npj Vaccines

Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection

(2020) Amy S. Espeseth et al.   npj Vaccines

A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice

(2020) Alec W. Freyn et al.   MOLECULAR THERAPY

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

(2020) Kizzmekia S. Corbett et al.   NATURE

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

(2020) Ugur Sahin et al.   NATURE

The disease burden of influenza beyond respiratory illness

(2020) Alejandro E. Macias et al.   VACCINE

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Back to the Future for Influenza Preimmunity—Looking Back at Influenza Virus History to Infer the Outcome of Future Infections

(2019) Magen Francis et al.   Viruses-Basel

Current and future influenza vaccines

(2019) Seiya Yamayoshi et al.   NATURE MEDICINE

Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy

(2019) Frank DeRosa et al.   MOLECULAR THERAPY

Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery

(2019) Piotr S. Kowalski et al.   MOLECULAR THERAPY

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

(2019) Robert A. Feldman et al.   VACCINE

Influenza Hemagglutinin and Neuraminidase: Yin–Yang Proteins Coevolving to Thwart Immunity

(2019) Ivan Kosik et al.   Viruses-Basel

Corrigendum: Induction of Robust B Cell Responses After Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells

(2019) Gustaf Lindgren et al.   Frontiers in Immunology

Protective Antibodies Against Influenza Proteins

(2019) Herbey O. Padilla-Quirarte et al.   Frontiers in Immunology

2754. Phase 1 Trial of an mRNA-Based Combination Vaccine Against hMPV and PIV3

(2019) Christine Shaw et al.   Open Forum Infectious Diseases

Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses

(2018) Annette B. Vogel et al.   MOLECULAR THERAPY

Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity

(2018) Shinu John et al.   VACCINE

NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?

(2018) Florian Krammer et al.   mBio

Influenza A Virus Cell Entry, Replication, Virion Assembly and Movement

(2018) Dan Dou et al.   Frontiers in Immunology

Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

(2018) Norbert Pardi et al.   Nature Communications

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

(2017) Martin Alberer et al.   LANCET

Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

(2017) Kapil Bahl et al.   MOLECULAR THERAPY

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

(2017) Norbert Pardi et al.   NATURE

Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics—An innate immune system standpoint

(2017) Yasmin Granot et al.   SEMINARS IN IMMUNOLOGY

Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells

(2017) Gustaf Lindgren et al.   Frontiers in Immunology

Tools for translation: non-viral materials for therapeutic mRNA delivery

(2017) Khalid A. Hajj et al.   Nature Reviews Materials

An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model

(2017) Jasdave S. Chahal et al.   Scientific Reports

Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery

(2016) Owen S. Fenton et al.   ADVANCED MATERIALS

Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses

(2016) Lauren Parker et al.   JOURNAL OF GENERAL VIROLOGY

Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines

(2016) Saranya Sridhar   Frontiers in Immunology

Influenza Vaccines: Challenges and Solutions

(2015) Katherine Houser et al.   Cell Host & Microbe

Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin

(2015) Michela Brazzoli et al.   JOURNAL OF VIROLOGY

135. Sequence-Engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals

(2015) Andreas Thess et al.   MOLECULAR THERAPY

Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs

(2015) Kevin J. Kauffman et al.   NANO LETTERS

Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines

(2015) Carlos A. DiazGranados et al.   VACCINE

mRNA-based therapeutics — developing a new class of drugs

(2014) Ugur Sahin et al.   NATURE REVIEWS DRUG DISCOVERY

Cellular immune correlates of protection against symptomatic pandemic influenza

(2013) Saranya Sridhar et al.   NATURE MEDICINE

Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice

(2013) Armin Hekele et al.   Emerging Microbes & Infections

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

(2012) Benjamin Petsch et al.   NATURE BIOTECHNOLOGY

Developing mRNA-vaccine technologies

(2012) Thomas Schlake et al.   RNA Biology

Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA

(2011) Katalin Karikó et al.   NUCLEIC ACIDS RESEARCH

Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability

(2008) Katalin Karikó et al.   MOLECULAR THERAPY